Dyne Therapeutics, Inc. (DYN) insider trading

By person

11 insiders · 130 transactions

9.5×

John G. Cox holds 9.5 times base salary in stock. $6.87M of shares against $721.00K in salary for 2025.

Salary from the company's own proxy. The shares are what John G. Cox last reported holding, valued at $16.00, the price Common Stock was last bought or sold at on the open market here, on 2 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Jason P Rhodes

Director

—

$129.10M (79) scheduled

−$129.10M

428,946

0.2297%

$6.86M

−91.4%

Dirk Kersten

Director

—

$38.57M (19) scheduled

−$38.57M

3,586,796

1.92%

$57.39M

−38.9%

John Cox

CEO & President

—

$443.69K (6) scheduled

−$443.69K

429,507

0.2300%

$6.87M

+457.8%

Brian S Posner

Director

$314.84K (8)

—

+$314.84K

27,000

0.0145%

$432.00K

+217.6%

Douglas Kerr

Head of R&D and CMO

—

$233.11K (7) scheduled

−$233.11K

170,564

0.0913%

$2.73M

+259.1%

Erick Lucera

Chief Financial Officer

—

$228.68K (4) scheduled

−$228.68K

119,766

0.0641%

$1.92M

—

Johanna Friedl-Naderer

Chief Commercial Officer

—

$43.38K (7) scheduled

−$43.38K

152,897

0.0819%

$2.45M

+161.8%

Oxana Beskrovnaya

Chief Scientific Officer

—

195,840

0.1049%

$3.13M

+39.5%

Richard William Scalzo

SVP, Head of Finance & Admin.

—

122,330

0.0655%

$1.96M

+24.1%

David Charles Lubner

Director

—

0.0000%

$0.00

−100.0%

Carlo Incerti

Director

—

0.0000%

$0.00

—

Dyne Therapeutics, Inc.

What the insiders did Mostly scheduled

By person